Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Does the Forecast Indicate for the Cystic Fibrosis (CF) Therapeutics Market From 2025 to 2029?
In recent times, the market size of therapeutics for cystic fibrosis (CF) has experienced robust growth. It is projected to expand from $7.63 billion in 2024 to $8.34 billion in 2025, showcasing a compound annual growth rate (CAGR) of 9.3%. The growth observed in the past years can be accredited to progress in targeted treatments, an increased comprehension of CF genetics, advocacy and awareness efforts for patients, government-backed research, the designation of orphan drugs, and incentives dedicated to the research of rare diseases.
In the coming years, a solid expansion is anticipated for the cystic fibrosis (CF) therapeutics market. It is projected to inflate to “$10.92 billion by 2029, experiencing a compound annual growth rate (CAGR) of 7.0%. The upsurge during the forecast period is ascribed to the surge in CF patient numbers, approvals for innovative therapies, emphasis on personalized medicine, an increase in biomarker study investments, enlarged newborn screening plans, and support from the healthcare policy. Key trends during the period predicted include the growth of CFTR modulators, gene manipulation technologies, early interference tactics, bettered diagnostic methodologies, telehealth and remote health checks, digitalization in healthcare, as well as management of chronic diseases.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9056&type=smp
What Elements Are Contributing To Growth In The Cystic Fibrosis (CF) Therapeutics Market?
The cystic fibrosis (CF) therapeutics market is expected to see substantial growth, propelled by a rise in the prevalence of cystic fibrosis patients. CF is a genetic disorder that severely impacts several bodily systems including the lungs, digestive system, and other organs. Therapeutics for cystic fibrosis aim to manage the disease by thinning the mucus in the lungs, making it simpler to clear. The escalating number of patients dealing with cystic fibrosis is anticipated to fortify the CF therapeutics market. For example, statistics shared by The Cystic Fibrosis (CF) Foundation in July 2022 reveal a surge in the cystic fibrosis population. In 2022, nearly 40,000 children and adults in the United States and more than 105,000 people globally were diagnosed with this disease. Consequently, the growing patient count is accelerating the growth of the cystic fibrosis (CF) therapeutics market.
Which Segments Are Detailed In The Global Cystic Fibrosis (CF) Therapeutics Market Report?
The cystic fibrosis (cf) therapeutics market covered in this report is segmented –
1) By Drug Class: Pancreatic Enzyme Supplements, Mucolytic, Bronchodilators, CFTR Modulators
2) By Route Of Administration: Oral, Inhaled
3) By Treatment Method: Medication, Devices
Subsegments:
1) By Pancreatic Enzyme Supplements: Lipase, Amylase, Protease
2) By Mucolytics: Dornase Alfa (Pulmozyme), Hypertonic Saline
3) By Bronchodilators: Short-Acting Beta Agonists (SABAs), Long-Acting Beta Agonists (LABAs), Anticholinergics
4) By CFTR Modulators: Ivacaftor, Lumacaftor Or Ivacaftor (Orkambi), Tezacaftor Or Ivacaftor (Symdeko), Elexacaftor Or Tezacaftor Or Ivacaftor
What Future Market Trends Are Projected For The Cystic Fibrosis (CF) Therapeutics Industry?
Leading businesses in the cystic fibrosis (CF) therapeutics sector are revolutionizing patient care and treatment solutions, including the cystic fibrosis innovation hub network, to hasten research, enrich treatment methods, and boost cooperative endeavors in creating novel treatments for CF patients. The cystic fibrosis innovation hub network is a collective initiative aimed at expediting the study and formulation of cystic fibrosis treatments. For example, LifeArc, a British charity and life sciences business dedicated to converting scientific studies into practical healthcare solutions, inaugurated the first Cystic Fibrosis Innovation Hub Network in the UK in October 2024. The Cystic Fibrosis Innovation Hub Network aims to augment cystic fibrosis (CF) treatments’ research and development by promoting alliances among healthcare providers, researchers, and patients. Introduced as part of a larger drive to hasten innovation in cystic fibrosis therapies, the hub concentrates on discovering new drug development routes and enhancing patient results.
Who Are The Key Contributors To Growth In The Cystic Fibrosis (CF) Therapeutics Market?
Major companies operating in the cystic fibrosis (CF) therapeutics market include Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche AG, Vertex Pharmaceuticals Incorporated, Chiesi Farmaceutici SpA, PTC Therapeutics LIMITED, Genentech Inc., Alaxia, AstraZeneca, Beyond Air Inc., Pfizer Inc., Alcresta Therapeutics Inc., Laurent Pharmaceuticals, Nestlé HealthScience, Pharmaxis, Bayer AG, AbbVie Inc., Novartis AG, Arcturus Therapeutics Holdings Inc., Arrowhead Pharmaceuticals Inc, ProQR Therapeutics N.V., Enterprise Therapeutics Ltd. , Corbus Pharmaceuticals Holdings Inc, Eloxx Pharmaceuticals , Translate Bio Inc, Zambon S.p.A
Get The Full Report Here:
Which Region Is Projected To Lead The Cystic Fibrosis (CF) Therapeutics Market By 2025?
North America was the largest region in the cystic fibrosis (CF) therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the cystic fibrosis (CF) therapeutics market during the forecast period. The regions covered in the cystic fibrosis (CF) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=9056&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model